Literature DB >> 2481642

Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.

S Ito1, N Tamura, T Fujita.   

Abstract

Decay-accelerating factor (DAF) is a 70,000 MW membrane protein that regulates the complement system on the cell surface. In the present study, we found that DAF had no effect on the classical pathway C3 and C5 convertases that had been stabilized by C4 nephritic factor (C4NeF). In DAF-incorporated cells, however, the assembly of the classical pathway C3 convertase was markedly inhibited even in the presence of C4NeF. C3 nephritic factor (C3NeF) in the alternative pathway protected the C3 convertase from the action of DAF to some extent, while the generation of C3 convertase was also inhibited by DAF. These results indicate that under physiological conditions, DAF functions to inhibit the assembly of C3 convertases even in the presence of nephritic factors, although it has no or little effect on the stabilized convertases. Thus, it is likely that DAF plays an important role in protection of host cells from damage by autologous complement in patients with nephritic factors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2481642      PMCID: PMC1385528     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Isolation and properties of a glycine-rich beta-glycoprotein of human serum.

Authors:  T Boenisch; C A Alper
Journal:  Biochim Biophys Acta       Date:  1970-12-22

2.  Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action.

Authors:  E M Hoffmann
Journal:  Immunochemistry       Date:  1969-05

3.  C3 inactivating factor in the serum of a patient with chronic hypocomplementaemic proliferative glomerulo-nephritis.

Authors:  R A Thompson
Journal:  Immunology       Date:  1972-01       Impact factor: 7.397

4.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

5.  Purification and structural analysis of the fourth component of human complement.

Authors:  C Bolotin; S Morris; B Tack; J Prahl
Journal:  Biochemistry       Date:  1977-05-03       Impact factor: 3.162

6.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

7.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

8.  Purification and characterization of decay-accelerating factor (DAF) from Raji cells.

Authors:  T Fujita; Y Shinkai; T Inoue; N Tamura
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

9.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

10.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  12 in total

Review 1.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

2.  Deficiency of CC chemokine ligand 2 and decay-accelerating factor causes retinal degeneration in mice.

Authors:  Minzhong Yu; Kai Kang; Ping Bu; Brent A Bell; Charles Kaul; James B Qiao; Gwen Sturgill-Short; Xiaoshan Yu; Matthew J Tarchick; Craig Beight; Sarah X Zhang; Neal S Peachey
Journal:  Exp Eye Res       Date:  2015-07-03       Impact factor: 3.467

Review 3.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

4.  Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.

Authors:  Marloes A H M Michels; Nicole C A J van de Kar; Marcin Okrój; Anna M Blom; Sanne A W van Kraaij; Elena B Volokhina; Lambertus P W J van den Heuvel
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

Review 5.  Factor B and C4b2a Autoantibodies in C3 Glomerulopathy.

Authors:  Jill J Hauer; Dingwu Shao; Yuzhou Zhang; Carla M Nester; Richard J H Smith
Journal:  Front Immunol       Date:  2019-04-04       Impact factor: 7.561

6.  Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.

Authors:  Marloes A H M Michels; Nicole C A J van de Kar; Ramon M van den Bos; Thea J A M van der Velden; Sanne A W van Kraaij; Sebastian A Sarlea; Valentina Gracchi; Michiel J S Oosterveld; Elena B Volokhina; Lambertus P W J van den Heuvel
Journal:  Front Immunol       Date:  2019-06-17       Impact factor: 7.561

7.  C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.

Authors:  Fei Zhao; Sara Afonso; Susanne Lindner; Andrea Hartmann; Ina Löschmann; Bo Nilsson; Kristina N Ekdahl; Lutz T Weber; Sandra Habbig; Gesa Schalk; Michael Kirschfink; Peter F Zipfel; Christine Skerka
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 7.561

8.  Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.

Authors:  Danielle Paixão-Cavalcante; Margarita López-Trascasa; Lillemor Skattum; Patricia C Giclas; Timothy H Goodship; Santiago Rodríguez de Córdoba; Lennart Truedsson; B Paul Morgan; Claire L Harris
Journal:  Kidney Int       Date:  2012-08-01       Impact factor: 10.612

9.  Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.

Authors:  Anna M Blom; Fernando Corvillo; Michal Magda; Grzegorz Stasiłojć; Pilar Nozal; Miguel Ángel Pérez-Valdivia; Virginia Cabello-Chaves; Santiago Rodríguez de Córdoba; Margarita López-Trascasa; Marcin Okrój
Journal:  J Clin Immunol       Date:  2016-05-05       Impact factor: 8.317

10.  Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.

Authors:  Roberta Donadelli; Patrizia Pulieri; Rossella Piras; Paraskevas Iatropoulos; Elisabetta Valoti; Ariela Benigni; Giuseppe Remuzzi; Marina Noris
Journal:  Front Immunol       Date:  2018-10-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.